Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix
NCT00026260Phase 2Completed
- Sponsor
- GOG Foundation
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of semaxanib in Cervical Cancer (CC), sponsored by GOG Foundation. Primary endpoints: Progression-Free Survival at 6 months, Time to Progression up to 5 years and 1 more. Status: completed.
02
Drugs
semaxanib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00026260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026260.